What seemed impossible 50 years ago is today becoming a reality as ‘soft drugs’ such as cannabis are being decriminalized and accepted for their calming effects as well as their legitimate medicinal properties. Several countries have now made the possession of cannabis legal, with others considering this, while the coffee shops in the Netherlands have been supplying cannabis in different forms for many years. It is now the turn of kava to be re-evaluated, to see whether there are properties in this plant that might be readily substituted for more conventional and harmful drugs, for instance tobacco and alcohol. However, as highlighted by Norton and Ruze (1994), kava like cannabis, has an enduring reputation that still makes it difficult for many to accept. Kava has been mythologized as an illicit alcohol, highly addictive, and causing physical harm. When examining the history of kava use in traditional contexts and considering the evidence now available, it is possible to demythologize this characterization. Looking at the potential benefits, it is time to re-brand kava, not only on the grounds as a relaxant, but in possessing life enhancing medicinal properties and as an alternative to alcohol, understanding that will be beneficial to policy makers, doctors and pharmacists.
Abbott P (2016) Kava: A review of the safety of traditional and recreational beverage consumption. Technical report). Rome: Food and Agriculture Organization of the United Nations and World Health Organization.
2.
Adams C (1998) Fiji loses its wonder drug to Western stressbusters. The Guardian, 8 October, p. 19.
Aporosa SA (2014) Yaqona (Kava) and Education in Fiji: Investigating ‘Cultural Complexities’ from a Post-development Perspective, Albany, NY: Massey University, Directorate Pasifika@Massey.
5.
AporosaSA (2015) The new kava user: Diasporic identity formation in reverse. New Zealand Sociology30: 58–77.
6.
Aporosa SA (2017a) Kava (Piper methysticum): Demythifying the Pacific's cultural keystone species. Tālanga Seminar Series. University of the South Pacific, Tonga, 12 October. Available at: https://researchcommons.waikato.ac.nz/handle/10289/12255.
7.
AporosaSA (2017b) Understanding cognitive functions related to driving following kava (Piper methysticum) use at traditional consumption volumes. Journal of Psychopharmacology31(Suppl.): A84.
Aporosa SA (2019b) Kava and ethno-cultural identity in Oceania. In: Ratuva S (ed.) The Palgrave Handbook of Ethnicity. Chapter 134-1. London: Springer-Nature, pp. 1–15.
10.
AporosaSATomlinsonM (2014) Kava hangover and gold-standard science. Anthropologica (Journal of the Canadian Anthropology Society)56: 163–175.
11.
AronsonJK (2008) Meyler's Side Effects of Herbal Medicines, Amsterdam: Elsevier.
12.
Australian Customs and Border Protection Service (2011) Kava (restricted import). Australian Government, 18 July. Available at: www.customs.gov.au/site/page4369.asp#e1065.
13.
Baker JD (2011) Tradition and toxicity: Evidential cultures in the kava safety debate. Social Studies of Science 41: 361–384.
14.
BarguilYChobletEWarterS, et al.(2013) Kava A nitric oxide synthase inhibition?Annales De Toxicologie Analytique25: 165–168.
BolatagiciT (2011) Export quality: Representing Fijian bodies and the economy of war. Asia Pacific Viewpoint52: 5–16.
20.
BonomoYNormanABiondoS, et al.(2019) The Australian drug harms ranking study. Journal of Psychopharmacology33(7): 759–768.
21.
Braun L and Cohen M (2010) Herbs and natural supplements: An evidence-based guide. Chatswood: Elsevier Australia.
22.
CagnacciAAranginoSRenziA, et al.(2003) Kava-kava administration reduces anxiety in perimenopausal women. Maturitas: The European Menopause Journal44: 103–109.
23.
CairneySCloughARMaruffP, et al.(2003) Saccade and cognitive function in chronic kava users. Neuropsychopharmacology28: 389–396.
CloughARWangZBailieRS, et al.(2004) Case–control study of the association between kava use and ischaemic heart disease in Aboriginal communities in eastern Arnhem Land (Northern Territory) Australia. Journal of Epidemiology Community Health58: 140–141.
28.
ConnorKMDavidsonJRChurchillLE (2001) Adverse-effect profile of kava. CNS Spectrum6: 848–853.
29.
Coomber R and South N (2004) Drug Use and Cultural Context ‘beyond the West’: Tradition, Change and Post-colonialism. London: Free Association Books.
30.
Corcuran M and Brynjolffssen S (2008) The root of Vanuatu's happiness. ABC Australia and Journeyman Pictures, 8 September. Available at: www.journeyman.tv/film/4270/kava-culture.
31.
Crowley T (1994) Proto who drank kava? In: Pawley A and Ross M (eds) Austronesian Terminologies: Continuity and Change (Pacific linguistics. Series C-127). Canberra: Department of Linguistics, Research School of Pacific and Asian Studies, The Australian National University, pp. 87–100.
32.
D'Abbs P (1995) The power of kava or the power of ideas? Kava use and kava policy in the Northern Territory, Australia. In: Pollock NJ (ed.) The Power of Kava. Canberra: Australian National University, pp. 166–183.
DegenhardtLWhitefordHAFerrariAJ, et al.(2013) Global burden of disease attributable to illicit drug use and dependence: Findings from the Global Burden of Disease Study 2010. The Lancet382(9904): 1564–1574.
GaoCOgeilRLloydB (2014) Alcohol's Burden of Disease in Australia, Australia: The Foundation for Alcohol Research and Education and Victorian Health Promotion Foundation.
GeierFPKonstantinowiczT (2004) Kava treatment in patients with anxiety. Phytotherapy Research18: 297–300.
46.
GolanDETashjianAHArmstrongEJ, et al.(2008) Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy, Baltimore, MD: Lippincott Williams & Wilkins.
GrazianoSOrsoliniLRotoloMC, et al.(2017) Herbal highs: Review on psychoactive effects and neuropharmacology. Current Neuropharmacology15: 750–761.
49.
GriswoldMGFullmanNHawleyC, et al.(2018) Alcohol use and burden for 195 countries and territories, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. The Lancet392: 1015–1035.
Hocart AM (1929) Lau Islands, Fiji. Honolulu: Bernice P Bishop Museum.
52.
HunterED'AbbsP (2003) In ‘modest but practical ways’: Medical practitioners and substance misuse in Aboriginal Australians. Internal Medicine Journal33: 333–335.
53.
Island Business (1989) Can kava kill? New worries about the drink of the Islands. Island Business, October, p. 51.
54.
KeltnerNLFolkesDG (2005) Psychotropic Drugs, St. Louis, MO: Elsevier Mosby.
55.
KetolaRAViinamäkiJRasanenI, et al.(2015) Fatal kavalactone intoxication by suicidal intravenous injection. Forensic Science International249: e7–e11.
KuchtaKSchmidtMNahrstedtA (2015) German kava ban lifted by Court: The alleged hepatotoxicity of kava (Piper methysticum) as a case of ill-defined herbal drug identity, lacking quality control, and misguided regulatory politics. Planta Medica81(18): 1647–1653.
Lebot V (1991) Kava (Piper methysticum Forst. f.): The Polynesian dispersal of an Oceanian plant. In: Cox PA and Banack SA (eds) Islands, Plants, and Polynesians: An Introduction to Polynesian Ethnobotany. Portland, OR: Dioscorides Press, pp. 169–201.
60.
LebotVCabalionP (1988) Kavas of Vanuatu: Cultivars of Piper methysticum Frost, Noumea: South Pacific Commission.
61.
LebotVLevesqueJ (1989) The origin and distribution of kava (Piper methysticum Frost. f., Piperaceae): A phytochemical approach. Allertonia2: 223–281.
62.
LebotVMerlinMLindstromL (1992) Kava: The Pacific Drug (Psychoactive Plants of the World Series), New Haven, CT: Yale University Press.
63.
LebotVMerlinMLindstromL (1997) Kava, the Pacific Elixir: The Definitive Guide to its Ethnobotany, History and Chemistry, Rochester, VT: Healing Arts Press.
64.
LemertEM (1967) Secular use of kava in Tonga. Quarterly Journal of Studies on Alcohol28: 328–341.
65.
LewinL (1998) Phantastica: A Classic Survey on the Use and Abuse of Mind-altering Plants, Randolph, VT: Park Street Press.
66.
LimTK (2016) Edible Medicinal and Non-medicinal Plants: Volume 11, Modified Stems, Roots, Bulbs, New York, NY: Springer.
67.
MaclennanKBrounéusFParkinL (2016) Public knowledge and desire for knowledge about drug safety issues: A survey of the general public in New Zealand. Pharmaceutical Medicine30: 339–348.
68.
Malani J (2002) Evaluation of the effects of kava on the liver. Report, 12 March. Suva: Fiji School of Medicine.
NayakMBPattersonDWilsnackSC, et al.(2019) Alcohol's secondhand harms in the United States: New data on prevalence and risk factors. Journal of Studies on Alcohol and Drugs80(3): 273–281.
74.
NortonSARuzeP (1994) Kava dermopathy. Journal of the American Academy of Dermatology31: 89–97.
75.
Moulds RFW (2009) Personal communication. Fiji School of Medicine, Suva.
76.
NuttDJKingLAPhillipsLD (2010) Drug harms in the UK: A multicriteria decision analysis. Lancet376: 1558–1565.
77.
New Zealand Government (2015) Standard 2.6.3 – Kava – Food Standards (Proposal P1025 – Code Revision) Variation – Australia New Zealand Food Standards Code – Amendment No. 154 (8 May). Available at: https://gazette.govt.nz/notice/id/2015-gs1906.
78.
PetticrewMMaani-HessariNKnaiC, et al.(2018) How alcohol industry organisations mislead the public about alcohol and cancer. Drug and Alcohol Review37: 293–303.
PoznyakVRekveD (2018) WHO: Global Status on Alcohol and Health, Switzerland: World Health Organisation.
81.
Procyk A and Lebot V (2013) Scientific Evidence does not Support Claims of Kava Toxicity. YouTube: The Vanuatu Department of Agriculture, 16 August. Available at: www.youtube.com/watch?v=aNRURSEuatU.
82.
Procyshyn RM, Bezchlibnyk-Butler KZ and Jeffries JJ (2017) Clinical Handbook of Psychotropic Drugs. Toronto: Hogrefe Publishing.
83.
Rasmussen P (2005) Submission on proposed reclassification of kava as a prescription medicine – Medicines Classification Committee, June. Auckland: New Zealand Association of Medical Herbalists.
84.
RatesSM (2001) Plants as source of drugs. Toxicon39: 603–613.
SarrisJStoughCBousmanCA, et al.(2013) Kava in the treatment of generalized anxiety disorder: A double-blind, randomized, placebo-controlled study. Journal of Clinical Psychopharmacology33: 643–648.
SchmidtMMorganMBoneK, et al.(2005) Kava: A risk-benefit assessment. In: MillsSBoneK (eds) The Essential Guide to Herbal Safety, St. Louis, MO: Elsevier, Churchill, Livingstone, pp. 155–221.
92.
ShowmanAFBakerJDLinaresC, et al.(2015) Contemporary Pacific and Western perspectives on ‘awa (Piper methysticum) toxicology. Fitoterapia100: 56–67.
93.
SinghYN (2009) Kava: An old drug in a new world. Cultural Critique71: 107–128.
94.
SinghYNBlumenthalM (1997) Kava: An overview. Distribution, mythology, botany, culture, chemistry and pharmacology of the South Pacific's most revered herb. HerbalGram (The Journal of the American Botanical Council)39: 34–56.
SteinerGG (2001) Kava as an anti craving agent: Preliminary data. Pacific Health Dialog8: 335–339.
97.
SteinmetzEF (1960) Piper Methysticum – Kava – Kava-Kava – yaqona: Famous Drug Plant of the South Sea Islands, Amsterdam: Steinmetz.
98.
StolermanIP (2010) Encyclopedia of Psychopharmacology, Heidelberg: Springer-Verlag.
99.
Tarbah F, Barguil Y, Weinmann W, et al. (2003) Death after consumption of kava beverage in combination with alcohol and cannabis. In: Pragst F and Aderjan R (eds) 13th GTFCh-Symposium: Ausgewaehlte Aspekte der Forensischen Toxikologie, Beitraege zum Symposium der Gesellschaft fuer Toxikologische und Forensische Chemie. 3–5 April, Mosbach, Germany. Heppenheim: Verlag Dr. Dieter Helm.
100.
ThompsonRRuchWHasenohrlRU (2004) Enhanced cognitive performance and cheerful mood by standardized extracts of Piper methysticum (Kava-kava). Journal of Human Psychopharmacology Clinical and Experimental19: 243–250.
101.
ThomsonP (2008) Kava in the Blood: A Personal and Political Memoir from the Heart of Fiji, Auckland: Publishing Press.
102.
ThurnEIMWhartonLC (1925) The Journal of William Lockerby: Sandlewood Trader in the Fijian Islands during the years 1808–1809, London: Hakluyt Society.
